Cargando…

The Role of Crosstalk between AR3 and E2F1 in Drug Resistance in Prostate Cancer Cells

Background: Drug resistance is one of the most prevalent causes of death in advanced prostate cancer patients. Combination therapies that target cancer cells via different mechanisms to overcome resistance have gained increased attention in recent years. However, the optimal drug combinations and th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Jin, Yang, Xi, Deshmukh, Dhanraj, Chen, Hegang, Fang, Shengyun, Qiu, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290672/ https://www.ncbi.nlm.nih.gov/pubmed/32354165 http://dx.doi.org/10.3390/cells9051094

Ejemplares similares

Regulation of p27 (Kip1) by Ubiquitin E3 Ligase RNF6
por: Deshmukh, Dhanraj, et al.
Publicado: (2022)

Crosstalk between KIF15 and AR in castrate-resistant prostate cancers
por: Yang, Hanny, et al.
Publicado: (2022)

SRC Kinase-Mediated Tyrosine Phosphorylation of TUBB3 Regulates Its Stability and Mitotic Spindle Dynamics in Prostate Cancer Cells
por: Alfano, Alan, et al.
Publicado: (2022)

Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth
por: Luo, Jun, et al.
Publicado: (2020)

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
por: Zheng, Zeyuan, et al.
Publicado: (2022)

6′-Sialyllactose Ameliorates In Vivo and In Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb–AR Pathway
por: Jin, Bo-Ram, et al.
Publicado: (2019)

Lysine Acetyltransferases and Their Role in AR Signaling and Prostate Cancer
por: Jaiswal, Bharti, et al.
Publicado: (2022)

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
por: Sugiura, Masahiro, et al.
Publicado: (2020)

Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer
por: Devlies, Wout, et al.
Publicado: (2021)

Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment
por: Raith, Fabio, et al.
Publicado: (2023)

Emerging proteins involved in castration-resistant prostate cancer via the AR-dependent and AR-independent pathways (Review)
por: Feng, Kangle, et al.
Publicado: (2023)

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
por: Narayanan, Ramesh
Publicado: (2020)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
por: Labaf, Maryam, et al.
Publicado: (2022)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Novel non-AR therapeutic targets in castrate resistant prostate cancer
por: Toren, Paul J., et al.
Publicado: (2013)

Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
por: Handle, Florian, et al.
Publicado: (2019)

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
por: He, Yundong, et al.
Publicado: (2021)

Huaier Extract Inhibits Prostate Cancer Growth via Targeting AR/AR-V7 Pathway
por: Liu, Zhengfang, et al.
Publicado: (2021)

AR Splicing Variants and Resistance to AR Targeting Agents
por: Kanayama, Mayuko, et al.
Publicado: (2021)

AR, the cell cycle, and prostate cancer
por: Balk, Steven P., et al.
Publicado: (2008)

Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism
por: Shah, Supriya, et al.
Publicado: (2016)

LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance
por: Zhang, Boya, et al.
Publicado: (2021)

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
por: Kallio, Heini M. L., et al.
Publicado: (2018)

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer()()
por: Qiao, Yuanyuan, et al.
Publicado: (2016)

Selective degradation of AR-V7 to overcome castration resistance of prostate cancer
por: Liu, Yuan, et al.
Publicado: (2021)

A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer
por: Isebia, Khrystany T., et al.
Publicado: (2023)

AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer
por: Yin, Linglong, et al.
Publicado: (2023)

KAT2A-mediated AR translocation into nucleus promotes abiraterone-resistance in castration-resistant prostate cancer
por: Lu, Dingheng, et al.
Publicado: (2021)

Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer
por: Qu, Yuanyuan, et al.
Publicado: (2015)

HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network
por: Ramos-Montoya, Antonio, et al.
Publicado: (2014)

GABARAPL1 Promotes AR+ Prostate Cancer Growth by Increasing FL-AR/AR-V Transcription Activity and Nuclear Translocation
por: Su, Bing, et al.
Publicado: (2019)

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
por: Kim, Dae-Hwan, et al.
Publicado: (2021)

Non-nuclear AR Signaling in Prostate Cancer
por: Zamagni, Alice, et al.
Publicado: (2019)

Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer
por: Chauhan, Gaurav, et al.
Publicado: (2021)

Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer
por: Batth, Izhar, et al.
Publicado: (2016)

Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer
por: Khan, Farhan, et al.
Publicado: (2023)

Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer
por: Hamid, Agus Rizal A. H., et al.
Publicado: (2021)

Baicalein suppresses the androgen receptor (AR)-mediated prostate cancer progression via inhibiting the AR N-C dimerization and AR-coactivators interaction
por: Xu, Defeng, et al.
Publicado: (2017)

Androgen Receptor (AR)-TLR4 Crosstalk Mediates Gender Disparities in Hepatocellular Carcinoma Incidence and Progression
por: Han, Qiuju, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mg3s7k96ahfftb76mldtkjo15q